Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

The Motley Fool August 1, 2007 Billy Fisher	Overseas Growth Sparks OSI's Earnings OSI Pharmaceuticals continues to prosper, and it has Tarceva to thank. But what happens when Tarceva becomes obsolete around 2009? Investors, take note.
The Motley Fool February 27, 2007 Billy Fisher	OSI Eyeing Growth in '07 Despite recent mixed results, the pharmaceutical has higher hopes for the year. Investors, take note.
The Motley Fool May 5, 2005 Charly Travers	OSI's Cancer Blockbuster Tarceva will turn OSI Pharmaceuticals into a leading biotech.
The Motley Fool October 29, 2007 Billy Fisher	Tarceva Sales Thrive at OSI The pharmaceutical's net revenue jumps 77%. Amazingly enough, there's still room for further growth at OSI. Investors, take note.
The Motley Fool April 26, 2004 Alyce Lomax	Genentech's Lucky Day Genentech and OSI Pharmaceuticals jump in today's trading session after favorable trial results for a cancer drug.
The Motley Fool August 22, 2005 Rich Duprey	Fuzzy Outlook for OSI-Eyetech Merger OSI Pharmaceuticals appears to have little to gain from its purchase of Eyetech. The situation does offer an eye-opening lesson on the risks inherent in investing in such one-trick ponies.
The Motley Fool January 22, 2010 Brian Orelli	Pfizer's Great Data Won't Do Much The full data from a clinical trial testing Pfizer's Sutent in pancreatic cancer was truly amazing. Unfortunately, it's not going to do very much for the stock or Pfizer's bottom line.
The Motley Fool January 5, 2005 Charly Travers	AstraZeneca's Lead Evaporates Pulling an application for Iressa from the EU makes the drug a has-been.
The Motley Fool November 19, 2004 Charly Travers	A New Drug for Lung Cancer Genentech and OSI's launch of Tarceva brings a new choice in the treatment of lung cancer.
The Motley Fool May 28, 2009 Brian Orelli	Make Money, Fight Disease: The ASCO Preview The big cancer meeting is upon us.
The Motley Fool March 30, 2010 Brian Orelli	Invest in This Space at Your Own Risk Lung cancer is a tough foe for drugmakers.
Registered Rep. February 1, 2005 Bob Hirschfeld	Healing Investments New lung cancer drugs mean good news in both the doctor's office and on Wall Street.
The Motley Fool May 18, 2010 Brian Orelli	What Astellas' Purchase of OSI Means for Biotech Investors Stop buying for the potential takeout.
The Motley Fool December 30, 2009 Brian Orelli	Pfizer Pflubs -- You Expected Otherwise? Bad news, but rather expected.
The Motley Fool December 20, 2004 Charly Travers	More Trouble at Big Pharma AstraZeneca's lung cancer drug is not as effective as once hoped.
The Motley Fool May 25, 2005 Tom Taulli	Genentech's Vision Thing Genentech has been on fire. Now the challenge will be to manage the growth. Investors, take note.
The Motley Fool July 6, 2009 Brian Orelli	Lilly Shows Us How It's Done The company announces that the Food and Drug Administration had expanded the approval of its cancer drug, Alimta, to include maintenance therapy for nonsquamous, non-small cell lung cancer.
The Motley Fool April 12, 2005 Brian Gorman	Genentech's Cancer Quest The company's achievements in lung cancer further strengthen its reputation as a cancer fighter. Would-be investors are best served by waiting patiently.
The Motley Fool June 4, 2008 Brian Lawler	Erbitux's Deceptively Disappointing Results Poorly received lead-drug data batters ImClone shares.
The Motley Fool July 16, 2007 Brian Lawler	Slight Setback for ImClone ImClone announces a failed cancer study. Investors, take note.
The Motley Fool April 17, 2007 Brian Lawler	ImClone Loses an Indication ImClone's lead drug fails in a clinical trial. Investors, take note.
The Motley Fool December 3, 2004 W.D. Crotty	One Hot Biotech Stock Biomira reports favorable Phase II test results, sending the stock up 146%.
The Motley Fool April 27, 2004 Alyce Lomax	Imagining ImClone It's been hard to ignore the lure of cancer drugs over the last several days. Today, ImClone shares leapt after the company reported stellar first-quarter profits, boosted by its launch of colon cancer drug Erbitux.
The Motley Fool May 1, 2006 Nathan Parmelee	OSI Weighs Its Options The restaurant partnership could pursue many courses to unlock shareholder value. While performance came in slightly lower than expected, it also wasn't a large disappointment. Investors, take note.
The Motley Fool July 20, 2005 Stephen D. Simpson	Two Ways to Play Roche Trying to track Roche is a pain, so investors might want to think about Genentech instead.
The Motley Fool February 10, 2006 Dan Bloom	OSI Systems' Rays of Hope Things may improve over the next two years for the technology conglomerate's Rapiscan division. Investors, take note.
The Motley Fool November 6, 2006 Nathan Parmelee	Outback Offer a Little Underdone OSI Restaurant Partners' offer to go private for $40 a share is reasonable, but not great. Here's why.
The Motley Fool August 28, 2008 Rich Smith	OSI Sandbagged Its strong sales growth could soon be mired in quicksand, and rightfully so.
The Motley Fool November 21, 2008 Brian Orelli	The Comeback of the Century? AstraZeneca is trying to revive Iressa.
InternetNews October 16, 2007 Sean Michael Kerner	Microsoft: The Open Source Company Microsoft joins the open source community today with the blessing of the Open Source Initiative.
The Motley Fool February 7, 2008 Rich Smith	I Spy OSI OSI, the airport security checkpoint equipment manufacturer, beats analyst estimates for the fifth consecutive quarter.
The Motley Fool August 17, 2007 Brian Lawler	The Perfect Pharma Acquisition The pharmaceutical industry has been busy consolidating in the past year. With so much buying and selling going on, here is speculation on what would constitute the perfect pharma acquisition.
The Motley Fool July 12, 2006 Stephen D. Simpson	Genentech's Deceptive Disappointment A slight shortfall in one product's sales is not a valid cause for panic. However, investors' patience might be wearing a bit thin here. What's more, Genentech's neither cheap nor undiscovered.
The Motley Fool January 12, 2007 Matthew Crews	OSI: A Farewell Toast OSI Restaurant partners reports its last quarterly earnings before going private.
The Motley Fool January 26, 2009 Brian Orelli	Which One of These Is Not Like the Other? Bristol-Myers and Eli Lilly run into some comparability issues.
The Motley Fool March 23, 2004 David Nierengarten	Genentech's Star Power How much higher can Genentech go?
The Motley Fool June 21, 2011 Seth Jayson	A Hidden Reason Why the Future Looks Bright for OSI Systems Although OSI Systems shows inventory growth that outpaces revenue growth, the company may also display positive inventory divergence, suggesting that management sees increased demand on the horizon.
The Motley Fool June 6, 2006 Nathan Parmelee	OSI Has a Pirate On Board Pirate Capital urges OSI Restaurant Partners to speed up its shareholder value initiatives or prepare for a proxy battle. A little outside pressure can help to focus management on moving more quickly and also highlight the need to deliver on promises.
The Motley Fool October 11, 2005 Stephen D. Simpson	Genentech Generates Profits Whether you call it a biotech or a pharmaceutical, there's no disputing that Genentech is raking in some big bucks. Trying to value this stock is no treat, but growth-oriented investors should still have much to look forward to over the years.
The Motley Fool March 20, 2009 Rich Smith	Taxing the Alphabet, and Other Top Stories Morning news: Congress will tax bonuses paid to employees of bailout recipients at a 90% rate. Xerox cuts first-quarter guidance by 80%... Euro hits a new high...
InternetNews February 1, 2005 Michael Singer	OSI President Eric Raymond Steps Down The open source licensing group to expand the scope of its activities, with new board members.